Somatic mutations in the isocitrate dehydrogenase 2 gene (IDH2) contribute to the pathogenesis of acute myeloid leukaemia (AML) through the production of the oncometabolite 2-hydroxyglutarate (2HG) 1-8 . Enasidenib (AG-221) is an allosteric inhibitor that binds to the IDH2 dimer interface and blocks the production of 2HG by IDH2 mutants 9,10 . In a phase I/II clinical trial, enasidenib inhibited the production of 2HG and induced clinical responses in relapsed or refractory IDH2-mutant AML 11 . Here we describe two patients with IDH2-mutant AML who had a clinical response to enasidenib followed by clinical resistance, disease progression, and a recurrent increase in circulating levels of 2HG. We show that therapeutic resistance is associated with the emergence of second-site IDH2 mutations in trans, such that the resistance mutations occurred in the IDH2 allele without the neomorphic R140Q mutation. The in trans mutations occurred at glutamine 316 (Q316E) and isoleucine 319 (I319M), which are at the interface where enasidenib binds to the IDH2 dimer. The expression of either of these mutant disease alleles alone did not induce the production of 2HG; however, the expression of the Q316E or I319M mutation together with the R140Q mutation in trans allowed 2HG production that was resistant to inhibition by enasidenib. Biochemical studies predicted that resistance to allosteric IDH inhibitors could also occur via IDH dimer-interface mutations in cis, which was confirmed in a patient with acquired resistance to the IDH1 inhibitor ivosidenib (AG-120). Our observations uncover a mechanism of acquired resistance to a targeted therapy and underscore the importance of 2HG production in the pathogenesis of IDH-mutant malignancies.
Letter reSeArCH ( Fig. 1d ). Treatment with enasidenib led to a decline in leukaemic blasts in the bone marrow ( Fig. 1a and Extended Data Fig. 1a ), a reduction in plasma 2HG concentration to less than 1 μM (Fig. 1c) , and normalization of the absolute neutrophil count (Fig. 1b ). The variant allele frequency (VAF) for IDH2 R140Q remained in the 20-50% range ( Fig. 1d) , consistent with the observation that enasidenib promotes differentiation of IDH2-mutant blasts 8, 11, 12 . After 9 months of therapy, the patient developed recurrent neutropenia and reappearance of leukaemic blasts consistent with disease progression (Fig. 1a, b and Extended Data Fig. 1a ). Importantly, the plasma 2HG concentration had increased despite continuous treatment with enasidenib ( Fig. 1c) .
The second patient presented with AML that was refractory to cytarabine-based induction chemotherapy and subsequent therapy with an investigational DOT1L inhibitor (Fig. 1e ). The patient had an increased blast count, neutropenia, and an increased plasma 2HG concentration of more than 5 μM ( Fig. 1e-g and Extended Data Fig. 1b ). Next-generation sequencing of bone marrow cells demonstrated the presence of an IDH2 R140Q mutation (Fig. 1h ). Treatment with enasidenib induced a considerable reduction in the peripheral blast count, an increase in the absolute neutrophil count, and a decrease in the plasma 2HG concentration to less than 1 μM ( Fig. 1e -g and Extended Data Fig. 1b ). The VAF for IDH2 R140Q remained in the 15-40% range ( Fig. 1h ). After 6 months of continuous treatment with enasidenib, the patient developed progressive disease with a rise in leukaemic blasts ( Fig. 1e and Extended Data Fig. 1b ) and increased plasma 2HG levels ( Fig. 1g ).
We hypothesized that clinical resistance to enasidenib in the setting of a progressive increase in 2HG levels might be due to acquisition of a new somatic mutation that mediates drug resistance. In both cases, we identified new mutations in the IDH2 gene at the time of acquired resistance, missense mutations that resulted in a substitution of glutamine 316 with glutamate (Q316E) in the first patient and substitution of isoleucine 319 with methionine (I319M) in the second patient ( Fig. 1d , h). Droplet digital PCR (ddPCR) (Extended Data Table 1 ) demonstrated the secondary IDH2 mutations were not detectable before treatment with enasidenib. Thus, the secondary IDH2 mutations were either acquired during the course of treatment or originated in a rare subclone that was below the limit of detection of the ddPCR assay.
The identification of second-site mutations in IDH2 in the setting of acquired resistance to enasidenib therapy raised the possibility of a resistance mechanism similar to those previously reported for tyrosine kinases such as BCR-ABL and EGFR [13] [14] [15] [16] . The Q316E and I319M mutations are encoded in exon 7 of the IDH2 gene, whereas the neomorphic R140Q mutation is encoded upstream in exon 4 ( Fig. 2a ). To determine the allelic conformation of the different IDH2 mutations, we performed long-range PCR amplification of genomic DNA spanning exons 4-7 of IDH2 followed by subcloning and sequence analysis of individual clones ( Fig. 2a-c ). In the first patient, all clones with the IDH2 R140Q mutation were wild type at position Q316 ( Fig. 2b, d) , whereas all clones with the IDH2 Q316E mutation were wild type for R140 ( Fig. 2b, d ). We observed analogous results for the second patient, such that the IDH2 I319M and IDH2 R140Q mutations were observed exclusively in different clones ( Fig. 2c, e ). These data demonstrate that acquired resistance to enasidenib was associated with emergence of second-site mutations in trans on the IDH2 allele without the neomorphic R140Q mutation.
To investigate the potential significance of the Q316E and I319M mutations in IDH2, we mapped the mutations at Q316 and I319 to the recently published structure of an IDH2 dimer bound by enasidenib ( Fig. 3a ; RCSB Protein Data Bank (PDB) code 5I96) 9 . Q316 and I319 are located in the IDH2 dimer interface and are key residues that interact with enasidenib 9 (Extended Data Fig. 2 ). Structural modelling predicted that the Q316E mutation disrupts hydrogen bonding with enasidenib ( Fig. 3b ), whereas the I319M mutation creates steric hindrance that would impede binding of enasidenib ( Fig. 3c ). Even though the dimer interface is symmetrical and enasidenib is not, identical residues on either side of the interface can make different, but important, interactions with the drug ( Fig. 3a and Extended Data Fig. 2 ), allowing second-site mutations at the interface to function in trans (and potentially also in cis, see below).
We evaluated the effect of the Q316E and I319M mutations on IDH2 enzymatic function alone and in trans with the R140Q mutation. Expression of the Q316E or I319M mutations in Ba/F3 hematopoietic cells did not result in increased 2HG production, in contrast to the known effect of the R140Q mutation on neomorphic IDH2 function ( Fig. 3d ). Enasidenib dose-dependently reduced 2HG levels in Ba/F3 cells that co-expressed wild-type and R140Q-mutant IDH2 in trans, consistent with inhibition of mutant IDH2 enzymatic activity as previously described 9, 11, 12 (Fig. 3e and Extended Data Fig. 3a ). By contrast, Ba/F3 cells that expressed IDH2(R140Q) concurrently with either IDH2(Q316E) or IDH2(I319M) in trans continued to produce high levels of 2HG when exposed to enasidenib ( Fig. 3e and Extended Data Fig. 3a ), although this could be partially inhibited by higher doses of drug (Extended Data Fig. 3b ).
We next tested the effect of the Q316E and I319M mutations on the self-renewal of primary mouse haematopoietic stem/progenitor cells (HSPC) in which IDH2(R140Q) is expressed from the endogenous locus 17 . Enasidenib inhibited the serial-replating capacity of HSPCs that expressed both wild-type and R140Q mutant IDH2 in trans, consistent with inhibition of mutant IDH2-induced gain of self-renewal ( Fig. 3f ). However, primary mouse HSPCs that expressed IDH2(R140Q) in conjunction with Q316E or I319M in trans maintained serial replating in the presence of enasidenib ( Fig. 3f ). Similar findings were observed in a primary murine-derived leukaemia model, in which IDH2(R140Q) and the FLT3 internal tandem duplication (ITD) are expressed from Letter reSeArCH their endogenous loci 17 ( Fig. 3g and Extended Data Fig. 3c, d ). Cellpermeable 2HG exposure was sufficient to confer enasidenib-resistant serial-replating to Idh2 R140Q /Flt3 ITD -mutant HSPC (Fig. 3h ), supporting the hypothesis that restored 2HG production contributes to the resistance mediated by the IDH2 Q316E and I319M mutations.
We determined the effect of expressing IDH2(Q316E) in trans on response to enasidenib in vivo ( Fig. 3i, j) . Bone marrow HSPCs expressing IDH2(R140Q) were transduced with either IDH2 WT or IDH2 Q316E and used to reconstitute the hematopoietic system of recipient mice. Recipient mice were treated for 2 weeks with enasidenib, and IDH2 WT and IDH2 Q316E mutant allele frequencies were assessed before and after treatment. Enasidenib treatment reduced the proportion of IDH2 WT -transduced cells, whereas the frequency of IDH2 Q316Etransduced cells increased despite enasidenib treatment ( Fig. 3i and Extended Data Fig. 3e ; P = 0.008), consistent with a fitness advantage of IDH2 Q316E -transduced mutant cells during enasidenib therapy (see Fig. 1d ). Similarly, the expression of the IDH2(Q316E) mutation in trans conferred production of 2HG by IDH2 R140Q -mutant cells in vivo that was resistant to enasidenib treatment ( Fig. 3j ; P = 4 × 10 −7 ), consistent with the in vitro studies ( Fig. 3e-g) .
To rule out indirect cellular effects by which the Q316E and I319M mutants might induce resistance to IDH2 inhibitors, we purified IDH2 Asterisk indicates value of 0. i, j, Mice reconstituted with Idh2 R140Q bone marrow HSPCs transduced with IDH2 WT or IDH2 Q316E were subjected to 2 (i) or 4 (j) weeks of treatment with enasidenib (40 mg kg −1 twice daily) and assessed for WT or QE allele frequencies before and after treatment (i) or intracellular 2HG levels in bone marrow mononuclear cells (j). See Methods. Data are mean ± s.e.m. for n = 5 WT and n = 8 QE mice. P = 0.008 (i) or P = 4 × 10 −7 (j) by two-tailed t-test. k-l, In vitro enzyme assays measuring absolute velocity (k) and relative activity (l) of NADPHdependent reduction of α-ketoglutarate (αKG) by haemagglutinin (HA)precipitated IDH2 dimers purified from cells co-expressing IDH2 HA-RQ 
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enzymatic dimers constituted of R140Q-wild type, R140Q-Q316E, or R140Q-I319M and performed in vitro enzymatic reactions (Fig. 3k , l and Extended Data Fig. 4a, b ). We did not observe a difference in the ability of the Q316E and I319M mutants to form dimers compared to wild-type IDH2 (Extended Data Fig. 4c-e ). In vitro enzymatic reactions with purified IDH2 dimers, α-ketoglutarate and NADPH demonstrated that each complex consumed NADPH and produced 2HG at similar rates, although R140Q-I319M dimers catalysed the reaction faster ( Fig. 3k and Extended Data Fig. 4f ). The activity of purified R140Q-wild-type enzyme complexes was inhibited by enasidenib in a dose-dependent manner, whereas purified R140Q-Q316E and R140Q-I319M enzyme dimers retained substantive activity in the presence of enasidenib (Fig. 3k, l and Extended Data Fig. 4f ). These data demonstrate that although the Q316E and I319M mutations do not affect wild-type IDH2 enzymatic function, they can cooperate with the R140Q mutation in trans to maintain 2HG production and promote disease progression in the presence of enasidenib.
Although we observed the IDH2 Q316E and IDH2 I319M mutations in trans to the IDH2 R140Q mutation, it is possible that these mutations might also have the capability to induce enasidenib resistance when acquired in cis to IDH2 R140Q . We therefore tested the possibility that these resistance mutations might confer resistance to enasidenib when present in the same allele as IDH2 R140Q . Consistent with the effect observed in trans, the expression of the IDH2 Q316E or IDH2 I319M mutations in cis with IDH2 R140Q in Ba/F3 cells ( Fig. 4a and Extended Data Fig. 5a ) allowed for 2HG production that was not inhibited by enasidenib. In vitro enzymatic reactions with purified IDH2 dimers comprised of wild-type-R140Q/Q316E and wild-type-R140Q/I319M demonstrated that the enzymatic activity of these complexes was resistant to enasidenib ( Fig. 4b and Extended Data Fig. 5b-g) .
The experimental findings suggested that second-site mutations of IDH2 in cis also might mediate clinical resistance to enasidenib. Analysis of 14 patients with de novo resistance and 7 additional patients with acquired resistance to enasidenib did not identify any additional patients with second-site IDH2 mutations in either allele (Extended Data Table 2 ). Notably, we identified one patient with IDH1 R132Cmutant AML who developed acquired clinical resistance to the mutant IDH1 inhibitor ivosidenib (AG-120) with a recurrent increase in blood levels of 2HG (Fig. 4c, d) . In this patient, we identified a second-site mutation in IDH1 that resulted in substitution of serine 280 with phenylalanine (S280F) (Fig. 4e ). S280 in IDH1 is paralogous to I319 in IDH2 (Fig. 4f) . To determine the allelic conformation of the IDH1 mutations, we performed long-range PCR amplification of genomic DNA that encompassed both mutations followed by subcloning and Reactions contained purified enzyme (7.5 μg ml −1 ), NADPH (0.3 mM), αKG (5 mM), and either vehicle or increasing doses of AG-221 (0.1, 0.3, 1, 3, 10 or 30 μM). Data are mean ± 95% confidence intervals for triplicate reactions (duplicate reactions for WT + RQ/QE AG-221 3 μM and 30 μM). c-e, Clinical and laboratory features for patient X in relation to treatment with mutant IDH1 inhibitor ivosidenib (AG-120; blue box), including bone marrow blast percentage (c), plasma 2HG concentration (d), and VAF for mutations identified by targeted nextgeneration sequencing of bone marrow cells (e). f, Alignment of IDH1 and IDH2 protein sequences demonstrating that S280 of IDH1 corresponds to I319 of IDH2. g, Summary of Sanger sequencing results from patient X demonstrating that the IDH1 R132C neomorphic mutation and the IDH1 S280F mutation occur in cis on the same allele.
Letter reSeArCH sequence analysis of individual clones. All clones with the IDH1 R132C mutation also harboured the IDH1 S280F mutation, demonstrating that the putative IDH1 S280F resistance mutation was acquired in cis with the neomorphic IDH1 R132C mutation (Fig. 4g) .
In summary, we have identified a mechanism of acquired clinical resistance to a molecularly targeted therapy, in which a second-site mutation on the wild-type allele can cooperate with a heterozygous gain-of-function mutation on the other allele to induce therapeutic resistance. In theory, in trans resistance mutations may occur in other homomultimeric targets such as receptor tyrosine kinases. The possibility that in trans mutations of EGFR cysteine 797 (C797) could contribute to EGFR inhibitor resistance in cell lines has been reported, but it has not been observed to occur in vivo in the clinical context 18 . It remains unclear whether there may be a selective advantage to acquiring the IDH2 Q316E and IDH2 I319M mutations in trans versus in cis; however, we would predict that in cis mutations may be identified as an alternative mechanism of acquired resistance to mutant IDH2 inhibitors. Consistent with this hypothesis, we identified a patient with acquired resistance to IDH1 inhibition who acquired an analogous IDH1 second-site mutation in cis. The identification of the IDH dimer-interface mutations credentials the importance of IDH as a therapeutic target and underscores the crucial role of 2HG in the pathogenesis of IDH-mutant malignancies.
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Clinical specimens. The patients described were enrolled on the phase I/II studies NCT02074839 or NCT01915498 11 . Enrolment was open to all patients with relapsed or refractory AML with a mutation in IDH1 (NCT02074839) or IDH2 (NCT01915498) identified locally and confirmed centrally. Patients were required to be 18 years or older at the time of study entry. Both men and women were enrolled on the studies. Patients were required to have a performance status of 2 or better and adequate organ function as defined in the study protocols. Clinical data, blood and bone marrow samples from patients with AML were obtained after receiving written informed consent from patients. Approval was obtained from the Institutional Review Board at each institution participating in these clinical trials. Additional consent was obtained from participants at Memorial Sloan Kettering Cancer Center with analyses performed on the institutional biobanking protocol approved by the Institutional Review Board. Patient biospecimens were anonymized by creating unique identifiers with no associated protected health information (PHI) and keeping the key on a password-protected server. Data collection and research was performed in compliance with all relevant ethical regulations for human research participants. Absolute neutrophil counts and blast percentages were determined by standard clinical assays. Next-generation sequencing and determination of VAF were performed as previously described 12, 19 . IDH1-mutant AML samples were assessed by the FoundationOne Heme panel as previously described 12, 20 . Allele-specific sequencing and PCR assays. Genomic DNA was isolated from bone marrow mononuclear cells using the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's instructions. The following primers were used to amplify the IDH2 genomic region spanning exon 4 and exon 7: forward primer 5′-ATTCCTGTGCCCTCCTTTCT-3′; reverse primer 5′-CAG AGCCCACACATTTGCAC-3′. The ~2 kb PCR products were subcloned into a TA-cloning plasmid, followed by bacterial transformation, selection of individual bacterial colonies, isolation of plasmid DNA, and Sanger sequencing in the forward and reverse direction using the same primers. The IDH1 genomic region was cloned and sequenced in a similar matter with the following primers: forward 5′-ACCAACGACCAAGTCACCAA-3′; reverse 5′-CCCTGGAATGACCCTGTTCC-3′. IDH2 qPCR was performed with the following primers: R140R forward 5′-AGTCCCAATGGAACTATCCG-3′, R140Q forward 5′-AGTCCCAATGGAACTATCCA-3′, R140R/Q Reverse 5′-GGGGTGAAGACCATTTTGAA-3′, and with SYBR green reagent (Affymetrix). cDNA was prepared using the Verso cDNA synthesis kit (ThermoFisher). For ddPCR, an assay specific for each mutation was designed and ordered through Biorad. All reactions were performed on a QX200 ddPCR System (Biorad) and evaluated in technical duplicates. Reactions were partitioned into a median of ~16,000 droplets per well using the QX200 droplet generator and run on a 96-well thermal cycler. Plates were then analysed with the QuantaSoft v1.7 to assess the number of droplets positive for mutant or wildtype DNA. Cell culture and DNA constructs. Adherent 293T cells (purchased from ATCC) were maintained at low passage number in high glucose DMEM with 10% FBS, glucose 25 mM, glutamine 4 mM, penicillin 100 U ml −1 , and streptomycin 100 μg ml −1 and split every 2-3 days before reaching confluence. Suspension Ba/F3 cells (purchased from DSMZ) were maintained in RPMI with 10% FBS, mIL-3 3 ng ml −1 , penicillin 100 U ml −1 , and streptomycin 100 μg ml −1 . Cell lines were authenticated by Short Tandem Repeat (STR) profiling. Cell lines repeatedly tested negative for mycoplasma throughout the experimental period. Primary mouse HSPCs were isolated, transduced, and cultured in methylcellulose as previously described 6 . Colony forming unit (CFU) assays were performed in M3434 methylcellulose (Stem Cell Technologies) in the presence of DMSO, enasidenib (AG-221; Agios) at 50 nM, or (2R)-octyl-α-hydroxyglutarate (octyl-2HG; Cayman) at 0.5 mM. Colonies were counted every 7-10 days and re-plated. IDH2 DNA constructs with C-terminal HA or Flag tags were cloned by standard sitedirected mutagenesis (Agilent) and Gibson Assembly (New England Biolabs) into pCDNA3.1 (Addgene), MSCV-IRES-GFP (Addgene), or MSCV-IRES-mCherry (Addgene) vectors and verified by Sanger sequencing. For transient transfection experiments, 293T cells were transfected using polyethylenimine 21 . For retroviral infection experiments, supernatant from 293T cells transfected with helper virus and plasmids was collected after 72 h, filtered and applied to Ba/F3 parental cells or primary mouse HSPCs overnight. Then, 48 h after infection, GFP + and/or mCherry + cells were sorted by flow cytometry. Sorted cells were expanded and used for drug treatment experiments with enasidenib. Mouse experiments. All animal procedures were conducted in accordance with the Guidelines for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committees (IACUC) at Memorial Sloan Kettering Cancer Center. C57BL/6 Idh2 R140Q and Idh2 R140Q /Flt3 ITD mice were previously described 17 . Bone marrow transplant and treatment of mice were performed as previously described 17 . In brief, 8-16-week old C57BL/6 Idh2 R140Q female donor mice were treated with 5-flurouracil 0.15 mg g −1 , and bone marrow cells isolated 5 days after treatment. Cells were then infected with retrovirus encoding wild-type or Q316E mutant IDH2. Positive mCherry cells marking transduction were FACS sorted and injected into lethally irradiated 8-16-week old C57BL/6 wild-type female recipient mice (950 cGy) with 1.5 × 10 5 support marrow cells. Engrafted mice were then used as donors for secondary transplants into recipients that were used for treatment studies without randomization (n = 5 for IDH2 WT and n = 8 for IDH2 Q316E . Investigators were not blinded to treatment. Enasidenib was given at a dose of 40 mg kg −1 twice daily by oral gavage. After 2 weeks of drug treatment, allele burden was assessed through peripheral blood mCherry positivity in red blood cell-lysed samples. After 4 weeks of drug treatment, the mice were euthanized, and bone marrow was harvested from femur and tibia bones by centrifugation for 1 min at 6,000g in 200 μl RPMI 10% FBS. Red blood cells were lysed in ACK (ammonium-chloride-potassium) lysis buffer. Cells were counted, pelleted, and frozen before 2HG analysis. Gel electrophoresis and western blotting. For denatured gel electrophoresis, cells were collected in 1× RIPA buffer (Cell Signaling), sonicated, centrifuged at 21,000g at 4 °C, and supernatants were collected. Cleared cell lysates were quantified by BCA assay (ThermoFisher) and normalized for total protein concentration. Samples were separated by SDS-PAGE, then either stained directly with Coomassie Blue Reagent or transferred to nitrocellulose membranes (Life Technologies), blocked in 5% milk prepared in TBS with 0.1% Tween 20 (TBST), incubated with primary antibodies overnight at 4 °C then horseradish peroxidase (HRP)-conjugated secondary antibodies (GE Healthcare; anti-mouse, NA931V, sheep, 1:5,000; anti-rabbit, NA934V, donkey, 1:5,000) for 1 h the following day. After incubation with ECL (ThermoFisher or GE Healthcare), digital imaging was performed using the Amersham Imager 600 (GE Healthcare) or film imaging was performed using the SRX-101A (Konica Minolta). Primary antibodies used included: anti-Flag (Sigma, F1804; clone M2; mouse; 1:1,000), anti-GAPDH (Cell Signaling Technology, 5174; clone D16H11; rabbit; 1:1,000), anti-HA (Cell Signaling Technology, 2367S; clone 6E2; mouse; 1:1,000), anti-IDH2 (Abcam, ab55271; no clone name; mouse; 1:1,000), and anti-vinculin (Cell Signaling Technology, 4650; no clone name; rabbit; 1:1,000). For native gel electrophoresis, cells were harvested in M-PER buffer (ThermoFisher) without sonication, IDH2 enzyme complexes were purified with Pierce Anti-HA Agarose (ThermoFisher), separated by NativePAGE (ThermoFisher), and either stained directly with Coomassie reagent or transferred for western blotting as described above. Enzyme assays. HA-tagged IDH2 enzymes were purified from transfected 293T cells using Pierce Anti-HA Agarose (ThermoFisher) according to the manufacturer's instructions. HA-tagged enzymes were quantified by denatured gel electrophoresis with Coomassie staining in reference to a defined quantity of recombinant human IDH2 (Abcam, ab198092). Purified enzymes were used at 7.5-10 μg ml −1 as indicated. NAPDH was used at 0.30 mM and α-ketoglutarate was used at 5 mM unless otherwise indicated. The enzyme reaction buffer consisted of HEPES 50 mM, NaCl 150 mM, MgCl 2 20 mM, and BSA 0.01%. For NADPH consumption assays, reactions were conducted in UV-transparent 96-well plates (Corning) with reaction volumes of 200 μl. A SpectraMax Plus 384 Microplate Reader (Molecular Devices) was used to monitor the absorbance at 340 nm every 30 seconds throughout the course of the reaction. For each condition, the mean rate of NADPH consumption for triplicate control reactions without enzyme was subtracted from the rate of NADPH consumption for triplicate experimental reactions with enzyme. Reaction velocities were calculated using an extinction coefficient for NADPH at ε340 of 6,220 M −1 cm −1 and pathlength of 0.56 cm for a 200 μl reaction volume in a standard 96-well plate. Metabolite extraction and analysis. Metabolites were extracted with ice-cold 80:20 methanol:water containing 2 μM deuterated 2-hydroxyglutarate (d-2hydroxyglutaric-2,3,3,4,4-d 5 acid; deuterated-2HG) as an internal standard. After overnight incubation at −80 °C, cell extract was collected, sonicated and centrifuged at 21,000g for 20 min at 4 °C to precipitate protein. Extracts were then dried in an evaporator (Genevac EZ-2 Elite). For gas chromatography-mass spectrometry (GC-MS), metabolites were resuspended by addition of 50 μl of methoxyamine hydrochloride (40 mg ml −1 in pyridine) and incubated at 30 °C for 90 min with agitation. Metabolites were further derivatized by addition of 80 μl of N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) plus 1% 2,2,2trifluoro-N-methyl-N-(trimethylsilyl)-acetamide, chlorotrimethylsilane (TCMS; Thermo Scientific) and 70 μl of ethyl acetate (Sigma) and incubated at 37 °C for 30 min. Samples were diluted 1:2 with 200 μl of ethyl acetate, then analysed using an Agilent 7890A GC coupled to Agilent 5975C mass selective detector. The GC was operated in splitless mode with constant helium carrier gas flow of 1 ml min −1 and with a HP-5MS column (Agilent Technologies). The injection volume was 1 μl and the GC oven temperature was ramped from 60 °C to 290 °C over 25 min. Peaks representing compounds of interest were extracted and integrated using MassHunter vB.08.00 (Agilent Technologies) and then normalized to both the internal standard (deuterated-2HG) peak area and cell number or protein content as applicable. Ions used for quantification of metabolite levels were 
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Experimental design 1. Sample size
Describe how sample size was determined.
No statistical methods were used to predetermine sample size. Sample size was based on experimental feasibilty, sample availability, and N necessary to obtain definitive results.
Data exclusions
Describe any data exclusions. None.
Replication
Describe whether the experimental findings were reliably reproduced.
All experimental findings were reproduced at least twice, with the exception of the in vivo data in Fig. 3i , j.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Randomization was not part of the design for the phase I/II trials NCT01915498 and NCT02074839. Randomization is not relevant to the current study as the object was to decipher the mechanisms of acquired clinical resistance to targeted therapies within individual patients.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not part of the design for the phase I/II trials NCT01915498 and NCT02074839. Blinding is not relevant to the current study as the object was to decipher the mechanisms of acquired clinical resistance to targeted therapies within individual patients.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
